Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | -1.85% | +17.99% | +33.67% |
Financials (USD)
Sales 2024 * | 87.81M | Sales 2025 * | 62.82M | Capitalization | 276M |
---|---|---|---|---|---|
Net income 2024 * | -88M | Net income 2025 * | -130M | EV / Sales 2024 * | 3.14 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.39 x |
P/E ratio 2024 * |
-2.89
x | P/E ratio 2025 * |
-2.27
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.06% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | -1.85% | ||
1 week | +17.99% | ||
Current month | -32.91% | ||
1 month | -26.39% | ||
3 months | +43.83% | ||
6 months | +78.24% | ||
Current year | +33.67% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.06 | -1.85% | 565,527 |
24-04-24 | 1.08 | -5.26% | 786,554 |
24-04-23 | 1.14 | +12.87% | 1,133,640 |
24-04-22 | 1.01 | +3.41% | 694,255 |
24-04-19 | 0.9767 | +8.72% | 1,482,450 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.67% | 276M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- ADAP Stock